drugset / Trial / NCT05992155

A Study of TAK-279 in Adults With or Without Kidney Problems

NCT05992155

Phase 1 Completed 24 enrolled Takeda
Non-randomizedParallel-groupOpen-labelBasic science

Summary

The main aim of this study is to find out how the body processes 1 dose of TAK-279 (pharmacokinetics) in participants with kidney problems compared to participants without kidney problems. Other aims are to check for side effects from TAK-279 and to learn how well participants tolerate 1 dose of TAK-279. The participants will need to stay at the clinic for 11 days.

Timeline

Start
2023-09-27
Primary completion
2024-05-22
Completion
2024-05-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Zasocitinib Small molecule 50 mg Oral